Remibrutinib

Remibrutinib is a small molecule drug that acts as a selective and covalent Bruton's tyrosine kinase (BTK) inhibitor. It is in development for the treatment of chronic spontaneous urticaria.^[1][2] In November 2023, Novartis announced that the compound "demonstrated clinically meaningful and statistically significant reduction in urticaria activity vs placebo" in a Phase III trial.^[3]

Remibrutinib

Clinical data
ATC code	L04AA60 (WHO)
Identifiers
IUPAC name N-[3-[6-Amino-5-[2-[methyl(prop-2-enoyl)amino]ethoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide
CAS Number	1787294-07-8
PubChem CID	118107483
IUPHAR/BPS	10457
DrugBank	DB16852
ChemSpider	78317000
UNII	I7MVZ8HDNU
ChEMBL	ChEMBL4483575
PDB ligand	N6Z (PDBe, RCSB PDB)
Chemical and physical data
Formula	C27H27F2N5O3
Molar mass	507.542 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C=C(C=C1NC(=O)C2=C(C=C(C=C2)C3CC3)F)F)C4=C(C(=NC=N4)N)OCCN(C)C(=O)C=C
InChI InChI=1S/C27H27F2N5O3/c1-4-23(35)34(3)9-10-37-25-24(31-14-32-26(25)30)20-12-18(28)13-22(15(20)2)33-27(36)19-8-7-17(11-21(19)29)16-5-6-16/h4,7-8,11-14,16H,1,5-6,9-10H2,2-3H3,(H,33,36)(H2,30,31,32) Key:CUABMPOJOBCXJI-UHFFFAOYSA-N